BD and EMS Launch Semaglutide GLP-1 Therapy in Brazil, Expanding Access
BDX sits 26% above its 52-week low of $127.536.
Summary
BD and Brazilian pharma EMS are launching a semaglutide therapy in Brazil, pairing EMS's drug with BD's Vystra™ injection pen platform. This marks BD's entry into the high-growth GLP-1 delivery market in a major emerging economy, leveraging its established pen technology. The collaboration addresses surging global demand for metabolic disease treatments and could open doors for similar partnerships. No financial terms were disclosed, but the deal strengthens BD's pharmaceutical systems segment and diversifies its revenue beyond traditional medical devices. The launch follows BD's strong Q2 results and raised guidance in May, adding a new growth vector.
At the time of this announcement, BDX was trading at $161.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $45.8B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.